Efficacy of Tanshinone Ⅱ A on animal models of acute ischemic stroke：a meta-analysis

doi:10.11817/j.issn.1673-9248.2023.02.009

Abstract

Abstract:

Objective

To systematically evaluate and analyze the efficacy of Tanshinone ⅡA on animal models of acute ischemic stroke.

Methods

The Cochrane Library, Embase, Web of Science, Medline databases, CNKI, Wanfang, VIP database were searched by the internet. Literature on the treatment of Tanshinone ⅡA in animal models of acute ischemic stroke was included from February 2003 to February 2021. Quality assessments were conducted for experimental animal studies according to STAIR (stroke therapy academic industry roundtable). Meta-analysis was performed through Revman 5.4 software.

Results

14 animal studies were finally included, involving a total of 218 animals, of which 114 were administered Tanshinone ⅡA, and the other 104 were in the control group (excipients control group). Meta-analysis showed a significant decrease in cerebral infarction volume (SMD=-3.12, 95% CI: -3.59--2.65) and neuroscore (SMD=-1.87, 95% CI: -2.35--1.39) in the acute ischemic stroke group compared with the control group with statistically significant difference (P＜0.0001).

Conclusion

Tanshinone ⅡA has a good therapeutic effect on animal models of acute ischemic stroke, and has shown a good neuroprotective effect, which means Tanshinone ⅡA is a relatively safe traditional Chinese medicine preparation.

Key words: Tanshinone ⅡA, Ischemic stroke, Neurofunction score

Jiamin Qiu, Huiyi Jiang, Tao Tao. Efficacy of Tanshinone Ⅱ A on animal models of acute ischemic stroke：a meta-analysis[J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(02): 136-144.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnxgbzz.cma-cmc.com.cn/EN/10.11817/j.issn.1673-9248.2023.02.009

https://zhnxgbzz.cma-cmc.com.cn/EN/Y2023/V17/I02/136

Figures/Tables 7

References 32

1	Johnson CO, Nguyen M, Roth GA, et al. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 [J]. Lancet Neurol, 2019, 18(5): 439-458.
2	Campbell BCV, Khatri P. Stroke [J]. Lancet, 2020, 396(10244): 129-142.
3	Daniele SG, Trummer G, Hossmann KA, et al. Brain vulnerability and viability after ischaemia [J]. Nat Rev Neurosci, 2021, 22(9): 553-572.
4	Campbell BCV, De Silva DA, Macleod MR, et al. Ischaemic stroke [J]. Nat Rev Dis Primers, 2019, 5(1): 70.
5	Chen M, Liu M, Luo Y, et al. Celastrol protects against cerebral ischemia/reperfusion injury in mice by inhibiting glycolysis through targeting HIF-1α/PDK1 axis [J]. Oxid Med Cell Longev, 2022, 2022: 7420507.
6	Tao T, Liu M, Chen M, et al. Natural medicine in neuroprotection for ischemic stroke: challenges and prospective [J]. Pharmacol Ther, 2020, 216: 107695.
7	Yu L, Tao J, Zhao Q, et al. Confirmation of potential neuroprotective effects of natural bioactive compounds from traditional medicinal herbs in cerebral ischemia treatment [J]. J Integr Neurosci, 2020, 19(2): 373-384.
8	吴筱霓, 刘伟, 何玉华, 等. 丹参酮ⅡA药理作用研究进展 [J]. 中国药业, 2020, 29(21): 93-97.
9	Su CY, Ming QL, Rahman K, et al. Salvia miltiorrhiza: Traditional medicinal uses, chemistry, and pharmacology [J]. Chin J Nat Med, 2015, 13(3): 163-182.
10	Tang C, Xue H, Bai C, et al. The effects of Tanshinone ⅡA on blood-brain barrier and brain edema after transient middle cerebral artery occlusion in rats [J]. Phytomedicine, 2010, 17(14): 1145-1149.
11	Longa EZ, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats [J]. Stroke, 1989, 20(1): 84-91.
12	Chen J, Li Y, Wang L, et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats [J]. Stroke, 2001, 32(4): 1005-1011.
13	Garcia JH, Wagner S, Liu KF, et al. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation [J]. Stroke, 1995, 26(4): 627-634; discussion 635.
14	Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development [J]. Stroke, 1999, 30(12): 2752-2758.
15	Wang L, Xiong X, Zhang X, et al. Sodium Tanshinone ⅡA sulfonate protects against cerebral ischemia-reperfusion injury by inhibiting autophagy and inflammation [J]. Neuroscience, 2020, 441: 46-57.
16	Cai M, Guo Y, Wang S, et al. Tanshinone ⅡA elicits neuroprotective effect through activating the nuclear factor erythroid 2-related factor-dependent antioxidant response [J]. Rejuvenation Res, 2017, 20(4): 286-297.
17	Chen Y, Wu X, Yu S, et al. Neuroprotection of Tanshinone ⅡA against cerebral ischemia/reperfusion injury through inhibition of macrophage migration inhibitory factor in rats [J]. PLoS One, 2012, 7(6): e40165.
18	Chen Y, Wu X, Yu S, et al. Neuroprotective capabilities of Tanshinone ⅡA against cerebral ischemia/reperfusion injury via anti-apoptotic pathway in rats [J]. Biol Pharm Bull, 2012, 35(2): 164-170.
19	Dong K, Xu W, Yang J, et al. Neuroprotective effects of Tanshinone ⅡA on permanent focal cerebral ischemia in mice [J]. Phytother Res, 2009, 23(5): 608-613.
20	Liu L, Zhang X, Wang L, et al. The neuroprotective effects of Tanshinone ⅡA are associated with induced nuclear translocation of TORC1 and upregulated expression of TORC1, pCREB and BDNF in the acute stage of ischemic stroke [J]. Brain Res Bull, 2010, 82(3-4): 228-233.
21	Li YH, Wang FY, Feng CQ, et al. Studies on the active constituents in radix salviae miltiorrhizae and their protective effects on cerebral ischemia reperfusion injury and its mechanism [J]. Pharmacogn Mag, 2015, 11(41): 69-73.
22	Tang Q, Han R, Xiao H, et al. Neuroprotective effects of Tanshinone ⅡA and/or tetramethylpyrazine in cerebral ischemic injury in vivo and in vitro [J]. Brain Res, 2012, 1488: 81-91.
23	Tang Q, Han R, Xiao HAN, et al. Protective effect of Tanshinone ⅡA on the brain and its therapeutic time window in rat models of cerebral ischemia-reperfusion [J]. Exp Ther Med, 2014, 8(5): 1616-1622.
24	Wang J, Ni G, Liu Y, et al. Tanshinone ⅡA promotes axonal regeneration in rats with focal cerebral ischemia through the inhibition of Nogo-A/NgR1/RhoA/ROCKII/MLC signaling [J]. Drug Des Devel Ther, 2020, 14: 2775-2787.
25	Wang L, Zhang X, Liu L, et al. Tanshinone Ⅱ A down-regulates HMGB1, RAGE, TLR4, NF-kappaB expression, ameliorates BBB permeability and endothelial cell function, and protects rat brains against focal ischemia [J]. Brain Res, 2010, 1321: 143-151.
26	Wen PY, Li J, Lu BL, et al. Tanshinone ⅡA increases levels of NeuN, protein disulfide isomerase, and Na⁺/K⁺-ATPase and decreases evidence of microglial activation after cerebral ischemic injury [J]. Neuroreport, 2016, 27(6): 435-444.
27	Yang L, Zhang B, Yin L, Cai B, et al. Tanshinone ⅡA prevented brain iron dyshomeostasis in cerebral ischemic rats [J]. Cell Physiol Biochem, 2011, 2011, 27(1): 23-30.
28	叶龙彬, 奚涛, 陈峰, 等. 丹参酮ⅡA对大鼠局灶性脑缺血再灌注损伤的保护作用 [J]. 中国药科大学学报, 2004, 35(3): 267-270.
29	Zhou ZY, Zhao WR, Zhang J, et al. Sodium Tanshinone ⅡA sulfonate: A review of pharmacological activity and pharmacokinetics [J]. Biomed Pharmacother, 2019, 118: 109362.
30	Chen L, Guo QH, Chang Y, et al. Tanshinone ⅡA ameliorated endothelial dysfunction in rats with chronic intermittent hypoxia [J]. Cardiovasc Pathol, 2017, 31: 47-53.
31	Li X, Wu Y, Zhang W, et al. Pre-conditioning with Tanshinone ⅡA attenuates the ischemia/reperfusion injury caused by liver grafts via regulation of HMGB1 in rat Kupffer cells [J]. Biomed Pharmacother, 2017, 89: 1392-400.
32	Lin L, Jadoon SS, Liu SZ, et al. TanshinoneⅡA ameliorates spatial learning and memory deficits by inhibiting the activity of ERK and GSK-3β [J]. J Geriatr Psychiatry Neurol, 2019, 32(3): 152-163.

纳入研究	干预措施	动物模型（实验组/对照组，只）	卒中模型	给药方式	结局指标	质量评价[质量级别（满足条目），类（个）]
Cai M 2017^[16]	丹参酮ⅡA	雄性 Nrf2 敲除小鼠（Nrf2 KO）（7/7）	短暂性大脑中动脉栓塞（1 h）	再灌注后10 min给药，腹腔注射，25 mg/kg	神经功能评分、脑梗死体积	Ⅰ（9）
Chen Y 2012^[17]	丹参酮ⅡA	雄性SD大鼠（6/6）	短暂性大脑中动脉栓塞（2 h）	再灌注后10 min给药，腹腔注射，25 mg/kg	神经功能评分、脑梗死体积	Ⅱ（7）
Chen Y 2012^[18]	丹参酮ⅡA	雄性SD大鼠（6/6）	短暂性大脑中动脉栓塞（2 h）	再灌注后10 min给药，腹腔注射，25 mg/kg	神经功能评分、脑梗死体积	Ⅰ（10）
Dong K 2009^[19]	丹参酮ⅡA	SD小鼠（9/3）	永久性大脑中动脉栓塞	造模前24 h和30 min给予腹腔注射20 mg/kg，造模后4 h重复腹腔注射20 mg/kg	神经功能评分、脑梗死体积	Ⅰ（9）
Liu L 2010^[20]	丹参酮ⅡA	雄性SD大鼠（23/23）	右侧大脑中动脉栓塞	缺血发作后15 min腹腔注射给药20 mg/kg	神经功能评分、脑梗死体积	Ⅰ（9）
Li YH 2015^[21]	丹参酮ⅡA	雄性Wistar大鼠（8/8）	短暂性左侧大脑中动脉栓塞（90 min）	再灌注后静脉注射给药40 mg/kg	神经功能评分、脑梗死体积	Ⅱ（5）
Tang C 2010^[10]	丹参酮ⅡA	SD大鼠（6/6）	短暂性大脑中动脉栓塞（2 h）	手术后5 min腹腔注射给药30 mg/kg	脑梗死体积	Ⅱ（5）
Tang Q 2012^[22]	丹参酮ⅡA	雄性SD大鼠（4/4）	永久性大脑中动脉栓塞	胃内给药30 mg/（kg·d），1次/d，持续5 d即术前3 d，术后4 h和24 h	神经功能评分、脑梗死体积	Ⅰ（9）
Tang Q 2014^[23]	丹参酮ⅡA	雄性SD大鼠（8/8）	颈总动脉结扎法	再灌注后1、4、6、12 h腹腔内给药25 mg/kg，1次/d，连续3 d	神经功能评分、脑梗死体积	Ⅰ（8）
Wang J 2020^[24]	丹参酮ⅡA	SD大鼠（5/5）	永久性大脑中动脉栓塞	手术后15 min腹腔注射给药20 mg/kg，1次/d，连续7 d	神经功能评分、脑梗死体积	Ⅰ（10）
Wang L 2010^[25]	丹参酮ⅡA	雄性SD大鼠（6/6）	永久性大脑中动脉栓塞	造模后立即腹腔注射给药20 mg/kg	神经功能评分、脑梗死体积	Ⅰ（9）
Wen PY 2016^[26]	丹参酮ⅡA	雄性SD大鼠（8/4）	短暂性大脑中动脉栓塞（2 h）	造模后腹腔注射8 mg/（kg·d），连续给药15 d	神经功能评分、脑梗死体积	Ⅰ（10）
Yang L 2011^[27]	丹参酮ⅡA	雄性Wistar大鼠（10/10）	短暂性大脑中动脉栓塞（2 h）	胃内给药20 mg/（kg·d），连续7 d	脑梗死体积	Ⅱ（7）
叶龙彬 2004^[28]	丹参酮ⅡA	SD大鼠（8/8）	短暂性大脑中动脉栓塞（2 h）	手术前连续灌胃给药3 d，1次/d，25 mg/kg	神经功能评分、脑梗死体积	Ⅱ（6）

纳入研究	干预措施	动物模型（实验组/对照组，只）	卒中模型	给药方式	结局指标	质量评价[质量级别（满足条目），类（个）]
Cai M 2017^[16]	丹参酮ⅡA	雄性 Nrf2 敲除小鼠（Nrf2 KO）（7/7）	短暂性大脑中动脉栓塞（1 h）	再灌注后10 min给药，腹腔注射，25 mg/kg	神经功能评分、脑梗死体积	Ⅰ（9）
Chen Y 2012^[17]	丹参酮ⅡA	雄性SD大鼠（6/6）	短暂性大脑中动脉栓塞（2 h）	再灌注后10 min给药，腹腔注射，25 mg/kg	神经功能评分、脑梗死体积	Ⅱ（7）
Chen Y 2012^[18]	丹参酮ⅡA	雄性SD大鼠（6/6）	短暂性大脑中动脉栓塞（2 h）	再灌注后10 min给药，腹腔注射，25 mg/kg	神经功能评分、脑梗死体积	Ⅰ（10）
Dong K 2009^[19]	丹参酮ⅡA	SD小鼠（9/3）	永久性大脑中动脉栓塞	造模前24 h和30 min给予腹腔注射20 mg/kg，造模后4 h重复腹腔注射20 mg/kg	神经功能评分、脑梗死体积	Ⅰ（9）
Liu L 2010^[20]	丹参酮ⅡA	雄性SD大鼠（23/23）	右侧大脑中动脉栓塞	缺血发作后15 min腹腔注射给药20 mg/kg	神经功能评分、脑梗死体积	Ⅰ（9）
Li YH 2015^[21]	丹参酮ⅡA	雄性Wistar大鼠（8/8）	短暂性左侧大脑中动脉栓塞（90 min）	再灌注后静脉注射给药40 mg/kg	神经功能评分、脑梗死体积	Ⅱ（5）
Tang C 2010^[10]	丹参酮ⅡA	SD大鼠（6/6）	短暂性大脑中动脉栓塞（2 h）	手术后5 min腹腔注射给药30 mg/kg	脑梗死体积	Ⅱ（5）
Tang Q 2012^[22]	丹参酮ⅡA	雄性SD大鼠（4/4）	永久性大脑中动脉栓塞	胃内给药30 mg/（kg·d），1次/d，持续5 d即术前3 d，术后4 h和24 h	神经功能评分、脑梗死体积	Ⅰ（9）
Tang Q 2014^[23]	丹参酮ⅡA	雄性SD大鼠（8/8）	颈总动脉结扎法	再灌注后1、4、6、12 h腹腔内给药25 mg/kg，1次/d，连续3 d	神经功能评分、脑梗死体积	Ⅰ（8）
Wang J 2020^[24]	丹参酮ⅡA	SD大鼠（5/5）	永久性大脑中动脉栓塞	手术后15 min腹腔注射给药20 mg/kg，1次/d，连续7 d	神经功能评分、脑梗死体积	Ⅰ（10）
Wang L 2010^[25]	丹参酮ⅡA	雄性SD大鼠（6/6）	永久性大脑中动脉栓塞	造模后立即腹腔注射给药20 mg/kg	神经功能评分、脑梗死体积	Ⅰ（9）
Wen PY 2016^[26]	丹参酮ⅡA	雄性SD大鼠（8/4）	短暂性大脑中动脉栓塞（2 h）	造模后腹腔注射8 mg/（kg·d），连续给药15 d	神经功能评分、脑梗死体积	Ⅰ（10）
Yang L 2011^[27]	丹参酮ⅡA	雄性Wistar大鼠（10/10）	短暂性大脑中动脉栓塞（2 h）	胃内给药20 mg/（kg·d），连续7 d	脑梗死体积	Ⅱ（7）
叶龙彬 2004^[28]	丹参酮ⅡA	SD大鼠（8/8）	短暂性大脑中动脉栓塞（2 h）	手术前连续灌胃给药3 d，1次/d，25 mg/kg	神经功能评分、脑梗死体积	Ⅱ（6）

[1]	Huijuan Shang, Xiaodong Yuan. Improvement of prognosis of acute cerebral ischemic stroke with edaravone dexkanol after mechanical thrombectomy [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2023, 09(05): 295-301.
[2]	Kechun Chen, Qiuyi Wu, Jian Li, Yin Zhou, Zhou Xu. Relationship between the first CT signs after mechanical thrombectomy and prognosis of patients based on different neutrophil-lymphocyte ratios [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2023, 13(04): 215-221.
[3]	Xiangning Ren, Xiaoming Zheng. Research progress of ischemic stroke and peripheral immune response [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2023, 13(03): 175-179.
[4]	Yuzhou Long, Hua Liu, Yunqian Zhang, Xingtong Li, Yunhu Fan, Zhengliang Shang, Zhenyu Song, Lihua Luo. Study on edaravone pretreatment prolonging thrombolytic time window by acute ischemic stroke and mechanism of ROS/TXNIP/NLRP3 pathway in rat [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2023, 13(02): 65-74.
[5]	Die Chen, Ying Guan, Xiao Han, Shaorong Xian. Clinical value of carotid artery color Doppler ultrasound combined with transcranial color coded sonography in evaluating therapeutic efficacy for ischemic stroke [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(03): 297-302.
[6]	Shoufa Zhao, Shu Wang, Larissa Miare Vados, Alberto Cantidio Ferreira. Observation on the efficacy of Xingnao Kaiqiao acupuncture combined with rehabilitation therapy in the treatment of ischemic stroke in the recorvery period [J]. Chinese Journal of Acupuncture and Moxibustion(Electronic Edition), 2023, 12(04): 151-155.
[7]	Xuping Zhang, Jiacheng Liu, Ge Zhang, Yanjiao Du, Shao Li, Dandan Shang, Hao Wang, Yan Li, Zhihui Duan. CYP2C19 gene polymorphism combined with thromboelastogram-guided antiplatelet therapy for patients with the large artery atherosclerosis and non-disabling ischemic cerebrovascular events (NICE) [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(05): 477-481.
[8]	Zeping Jin, Jing Dong, Yunpeng Liu, Yang Wang. Correlation between microbiota-gut-brain axis and the risk factors of ischemic stroke [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(05): 510-517.
[9]	Chenjun Yin, Zhe Zhang, Xiaoming Li. Advance in mechanisms of patent foramen ovale-associated thrombosis [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(04): 307-311.
[10]	Xin Li, Yongkai Li, Shuqing Jiang, Xarbatgul·Samat, Jianzhong Yang. Risk factors related to hemorrhage transformation after intravenous thrombolysis in acute ischemic stroke [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(04): 331-336.
[11]	Ying Deng, Shan Huang, Huixiu Hu, Chao Sun. Prevalence of risk factors in aged patients with ischemic stroke [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(04): 344-349.
[12]	Xingyun Yuan, Wanhong Chen, Liping Yu, Li Yao. Interventional treatment of vertebral artery occlusion with Wallenberg syndrome [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(04): 394-399.
[13]	Lingzhi Qiu, Ping Hu, Ting Luo, Hua Yan. Research progress of the relationship between lipoprotein(a) and atrial fibrillation [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(03): 280-284.
[14]	Jing Shi, Chenxi Hao, Miao He, Weirong Li. Research progress in interaction of circadian rhythm and silent information regulator 1 in neuroprotection against ischemic stroke [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(02): 154-158.
[15]	Hui Wang, Shujuan Zhang, Baohua Zhou, Qiong Yang, Yongmei Luo. Research progress in intravenous thrombolysis mode for ischemic stroke based on stroke unit [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(02): 150-153.

Please choose a citation manager

Content to export